Drug intelligence / Profile preview

busulfan + cyclophosphamide + antithymocyte globulin + granulocyte-colony stimulating factor

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous, Oral, Subcutaneous

Overview

A combination conditioning regimen used prior to hematopoietic stem cell transplantation. It consists of busulfan (an alkylating agent), cyclophosphamide (an immunosuppressive agent), antithymocyte globulin (for T-cell depletion), and granulocyte-colony stimulating factor (for stem cell mobilization). This regimen is designed to suppress the recipient's immune system, eliminate diseased cells, and create space for donor cells to engraft.

Other names: Bu/Cy/ATG/G-CSFATG-BuCy with G-CSF

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)DNA

Beyond the preview

Go deeper on busulfan + cyclophosphamide + antithymocyte globulin + granulocyte-colony stimulating factor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on busulfan + cyclophosphamide + antithymocyte globulin + granulocyte-colony stimulating factor.

Explore the full profile